<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103410</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 175/2021</org_study_id>
    <nct_id>NCT05103410</nct_id>
  </id_info>
  <brief_title>Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy</brief_title>
  <official_title>Impact of Preoperative Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The analgesic effect of perioperative use of aripiprazole has not been fully investigated.&#xD;
&#xD;
      So, this study aims to test the effects of aripiprazole versus placebo in reducing&#xD;
      postoperative pain following laparoscopic hysterectomy and to explore the potential side&#xD;
      effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First time to analgesic requirement</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>After extubation, an intravenous patient-controlled analgesia system, will be connected to the patient (Accufuser PlusÂ® 100 ml, Woo Young Medical Co, Korea) will be prepared with 60 ml normal saline containing 60 mg morphine, it will be programmed to give and 0.5 ml bolus dose with lockout interval of 8 minutes. Time to first Bolus will be estimated considering extubation time is the zero time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>Total morphine consumption per twenty four hours will be estimated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>First 24 hours postoperatively</time_frame>
    <description>Pain scores will be evaluated by a blinded observer anesthesiologist at the time of arrival in the PACU, and 10, 20, 30 minutes, 1 h, 2h, 4, 6, 8, 10, 12, 16 and 24 hr thereafter using visual analogue scale (VAS) (0-10 cm: 0 = no pain, 10 = the worst pain possible). The patients will be instructed about usage of VAS preoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anesthesia</condition>
  <condition>Analgesia</condition>
  <condition>Hysterotomy</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARIPiprazole 30 MG</intervention_name>
    <description>Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physical status American Society of Anesthesiologist (ASA) I or II&#xD;
&#xD;
          -  Electively scheduled for laparoscopic hysterectomy,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 30&#xD;
&#xD;
          -  ASA physical status &gt; II&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Major illnesses (e.g., cardiac, respiratory, renal, hepatic or neurological)&#xD;
&#xD;
          -  Coagulation abnormalities&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to aripiprazole or contraindications to its use (a psychiatric&#xD;
             illness, patients on antidepressants, dementia-related psychosis)&#xD;
&#xD;
          -  History of drug addiction or alcohol abuse&#xD;
&#xD;
          -  Mental retardation interfering with the evaluation of pain scores or PCA programs .&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amin Mohammed Alansary Amin Ahmed Helwa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

